CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Liso-Cel Shows Encouraging Clinical Activity, Safety in Relapsed/Refractory MCL

March 19th 2021

M Lia Palomba, MD, discusses the data from the TRANSCEND-NHL-001 trial and projected how lisocabtagene maraleucel could fit into the treatment paradigm for patients with MCL.

New CAR T-Cell Therapy Approvals Diversify Treatment Options in Large B-Cell Lymphoma

March 18th 2021

Matthew Lunning, DO, discusses discussed the findings from pivotal CAR T-cell therapy trials in LBCL, the potential to utilize these agents in the outpatient setting, how off-the-shelf allogeneic products could further transform outcomes, and the importance of shortening brain-to-vein time for this patient population.

Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma

March 17th 2021

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

Frontline Axi-Cel Elicits 74% CR Rate in High-Risk Large B-Cell Lymphoma

March 15th 2021

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relapsed/Refractory ALL

March 15th 2021

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden

mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma

March 8th 2021

A phase 2 clinical trial has been initiated to evaluate Descartes-11, an mRNA CAR T-cell therapy, as a consolidative therapy in patients with newly diagnosed, high-risk multiple myeloma who have residual disease after induction therapy.

FDA Approves Axi-Cel for Relapsed/Refractory Indolent Follicular Lymphoma

March 6th 2021

The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory indolent follicular lymphoma after 2 or more lines of systemic therapy.

Early Successes and Remaining Challenges of Harnessing Natural Killer Cells for Cancer Therapy

February 27th 2021

Natural killer cells can offer several advantages over T cells for CAR therapy in that the former uses both a CAR dependent and independent mechanism for tumor eradication, has better safety, and off-the-shelf feasibility—all at a potentially lower cost.

CD19-Targeted CAR T-Cell Therapies Induce Durable Remissions in Several Lymphoma Subtypes

February 26th 2021

CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.

Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies

February 26th 2021

Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.

Growing Body of Evidence Underscores the Activity and Safety of CAR T-cell Therapy in ALL

February 25th 2021

Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.

KTE-X19 Continues to Elicit Durable Responses in Relapsed/Refractory MCL

February 24th 2021

February 24, 2021 - The CAR T-cell product KTE-X19 continues to demonstrate durable clinical benefit in patients with relapsed/refractory mantle cell lymphoma, with an overall response rate of 92%.

CAR T-Cell Therapy Explodes on the Scene in Heavily Pretreated Multiple Myeloma

February 24th 2021

Binod Dhakal, MD, discusses the potential impact of ide-cel, orva-cel, and cilta-cel in multiple myeloma therapy.

Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products

February 23rd 2021

February 23, 2021 - AbbVie and Caribou Biosciences, Inc have entered into a collaboration and license agreement for the research and development of chimeric antigen receptory T-cell therapeutics.

CAR T-Cell Therapy Carves Out a Role in Multiple Myeloma

February 18th 2021

Yi Lin, MD, PhD, discusses promising data with CAR T-cell therapy in multiple myeloma.

Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma

February 17th 2021

Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.

Giants of Cancer Care Honorees June and Rosenberg Receive Prestigious Prize

February 17th 2021

February 17, 2021 - Carl H. June, MD, and Steven A. Rosenberg, MD, PhD, have received the 2021 Dan David Prize Laureate for their research in oncology. They, along with Zelig Eshhar, an immunologist at the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center, will share a prize of $1 million.

Braunschweig Makes the Case for Earlier Use of CAR T-Cell Therapy in DLBCL

February 16th 2021

CAR T-cell therapy has shown robust responses and curative potential in patients with diffuse large B-cell lymphoma, regardless of cytogenetics or age.

Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL

February 11th 2021

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Axi-Cel Active in Relapsed/Refractory B-Cell Lymphomas Irrespective of Chemo Sensitivity

February 9th 2021

February 9, 2021 - Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.